G-CSF filgrastim biosimilar-Sandoz reduces the incidence of febrile neutropenia in patients receiving chemotherapy regimens with rest periods not exceeding 14 days: A French, multicenter, prospective, non-interventional study

G-CSF filgrastim biosimilar-Sandoz reduces the incidence of febrile neutropenia in patients receiving chemotherapy regimens with rest periods not exceeding 14 days: A French, multicenter, prospective, non-interventional study

Purpose: The objective of this study was to describe filgrastim biosimilar-Sandoz modalities of use in patients receiving cytotoxic chemotherapy regimens with a rest period of ≤14 days and to investigate the incidence of febrile neutropenia (FN) in routine clinical practice. Methods: This was a Fren...

Full description

Bibliographic Details
Main Authors: Jean-Marc Phelip, Pierre-Jean Souquet, Maya Hacini, Mohamad Chehimi, Vincent Bourgeois, Ryma Bennoune, Olivier Tredan
Format: Article
Language:English
Published: Elsevier 2023-01-01
Series:Cancer Treatment and Research Communications
Subjects:
Filgrastim biosimilar
Febrile neutropenia
Supportive care
Online Access:http://www.sciencedirect.com/science/article/pii/S2468294223000114

Similar Items

Similar Items